4 completed, 2 terminated, 1 withdrawn. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow MCS110: new trials by email Literature Review of MCS110 trials Research Report on MCS110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). spartalizumab, LAG525, NIR178 - Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Novartis Pharmaceuticals | 64 | 2019-01-31 | 2025-05-18 |
| MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer MCS110, Doxorubicin, Cyclophosphamide - Breast Cancer, Cancer of Breast | Phase 1 | Withdrawn | Washington University School of Medicine | 2018-09-30 | 2018-08-16 | |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma MCS110, Dabrafenib, Trametinib - Melanoma | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 6 | 2018-09-10 | 2024-07-31 |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies MCS110, PDR001 - Triple Negative Breast Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 141 | 2016-06-29 | 2021-08-11 |
| Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) MCS110, carboplatin, gemcitabine - Advanced Triple Negative Breast Cancer (TNBC) With High TAMs | Phase 2 | Completed | Novartis Pharmaceuticals | 50 | 2015-08-10 | 2021-06-21 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2012-04-23 | 2021-01-05 |
| A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases MCS110 - Prostate Cancer, Bone Metastases | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 3 | 2008-09-01 | 2020-12-19 |
Melanoma (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Giant Cell Tumor of Tendon Sheath (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Synovitis, Pigmented Villonodular (1)
Novartis Pharmaceuticals (5) · Dana-Farber Cancer Institute (1) · Washington University School of Medicine (1)
United States (6) · Hong Kong (3) · Italy (3) · Spain (3) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Japan (2) · South Korea (2) · Switzerland (2) · Austria (1) · Finland (1) · Israel (1) · Netherlands (1)
Elizabeth I Buchbinder, MD (1) · Leonel Hernandez-Aya, M.D. (1)
2015 (1), 2016 (1), 2018 (1)